CY1107451T1 - Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου - Google Patents

Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου

Info

Publication number
CY1107451T1
CY1107451T1 CY20081100470T CY081100470T CY1107451T1 CY 1107451 T1 CY1107451 T1 CY 1107451T1 CY 20081100470 T CY20081100470 T CY 20081100470T CY 081100470 T CY081100470 T CY 081100470T CY 1107451 T1 CY1107451 T1 CY 1107451T1
Authority
CY
Cyprus
Prior art keywords
escitalopram
hydrobromic
preparing
citalopram
hydrobromide
Prior art date
Application number
CY20081100470T
Other languages
English (en)
Inventor
Lawrence Martel
Robert Dancer
Hans Petersen
Peter Ellegaard
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107451(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1107451T1 publication Critical patent/CY1107451T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Escitalopram (S-citalopram) εις την μορφήν του υδροβρωμικού του άλατος, μέθοδοι δια την παρασκευήν αυτού και φαρμακευτικάς συνθέσεις αυτού.
CY20081100470T 2002-12-23 2008-05-02 Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου CY1107451T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
EP03779759A EP1578738B1 (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Publications (1)

Publication Number Publication Date
CY1107451T1 true CY1107451T1 (el) 2012-12-19

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100470T CY1107451T1 (el) 2002-12-23 2008-05-02 Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου

Country Status (33)

Country Link
US (1) US20040167209A1 (el)
EP (1) EP1578738B1 (el)
JP (2) JP4658613B2 (el)
KR (1) KR20050086933A (el)
CN (1) CN100349885C (el)
AR (1) AR042652A1 (el)
AT (1) ATE388947T1 (el)
AU (1) AU2003287919B2 (el)
BR (1) BR0317623A (el)
CA (1) CA2511142A1 (el)
CY (1) CY1107451T1 (el)
DE (1) DE60319739T2 (el)
DK (1) DK1578738T3 (el)
EA (1) EA013116B1 (el)
EG (1) EG24729A (el)
ES (1) ES2298595T3 (el)
HK (1) HK1087708A1 (el)
IL (1) IL169125A0 (el)
IS (1) IS2654B (el)
ME (1) MEP5808A (el)
MX (1) MXPA05005772A (el)
MY (1) MY135468A (el)
NO (1) NO20053595L (el)
NZ (1) NZ540281A (el)
PE (1) PE20040924A1 (el)
PL (1) PL378275A1 (el)
PT (1) PT1578738E (el)
RS (1) RS51092B (el)
TW (1) TW200501943A (el)
UA (1) UA80170C2 (el)
UY (1) UY28148A1 (el)
WO (1) WO2004056791A1 (el)
ZA (1) ZA200504109B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
PT1578738E (pt) * 2002-12-23 2008-04-11 Lundbeck & Co As H Bromidrato de escitalopram e um método para a sua preparação
WO2005084643A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
BRPI0617382A2 (pt) * 2005-10-14 2017-07-11 H Lundbeck As Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
JP5501615B2 (ja) * 2006-07-11 2014-05-28 田辺三菱製薬株式会社 モルホリン化合物の塩
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
PL3694843T3 (pl) * 2017-10-09 2022-06-20 Hasleton, Mark Nowa sól i nowe stałe postacie escitalopramu
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
KR100411505B1 (ko) * 1998-10-20 2003-12-18 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조방법
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
DE69920526T2 (de) * 1999-10-25 2006-02-23 H. Lundbeck A/S Verfahren zur herstellung von citalopram
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
IS6021A (is) * 2000-08-10 2001-10-20 H. Lundbeck A/S Lyfjasamsetningar sem innihalda sítalópram
WO2002046339A2 (de) * 2000-12-04 2002-06-13 Dr. Frische Gmbh Verfahren zur vorbehandlung von rohölen und rohfetten für eine herstellung von fettsäureestern
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
AR034612A1 (es) 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
PT1578738E (pt) * 2002-12-23 2008-04-11 Lundbeck & Co As H Bromidrato de escitalopram e um método para a sua preparação
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Also Published As

Publication number Publication date
BR0317623A (pt) 2005-11-29
DK1578738T3 (da) 2008-06-30
PT1578738E (pt) 2008-04-11
IS2654B (is) 2010-08-15
MEP5808A (xx) 2010-02-10
DE60319739T2 (de) 2008-07-17
TW200501943A (en) 2005-01-16
HK1087708A1 (en) 2006-10-20
WO2004056791A1 (en) 2004-07-08
NO20053595L (no) 2005-09-05
PL378275A1 (pl) 2006-03-20
UA80170C2 (en) 2007-08-27
DE60319739D1 (de) 2008-04-24
RS51092B (sr) 2010-10-31
ES2298595T3 (es) 2008-05-16
EG24729A (en) 2010-06-21
US20040167209A1 (en) 2004-08-26
IS7848A (is) 2005-05-17
AU2003287919B2 (en) 2009-11-12
UY28148A1 (es) 2004-09-30
PE20040924A1 (es) 2004-12-11
MY135468A (en) 2008-04-30
ATE388947T1 (de) 2008-03-15
CA2511142A1 (en) 2004-07-08
JP2011037893A (ja) 2011-02-24
RS20050487A (en) 2007-06-04
AU2003287919A1 (en) 2004-07-14
MXPA05005772A (es) 2005-08-16
NZ540281A (en) 2008-07-31
EA200501046A1 (ru) 2005-12-29
EP1578738B1 (en) 2008-03-12
CN1726202A (zh) 2006-01-25
ZA200504109B (en) 2006-08-30
EP1578738A1 (en) 2005-09-28
CN100349885C (zh) 2007-11-21
KR20050086933A (ko) 2005-08-30
JP4658613B2 (ja) 2011-03-23
EA013116B1 (ru) 2010-02-26
JP2006514952A (ja) 2006-05-18
AR042652A1 (es) 2005-06-29
IL169125A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
CY1107451T1 (el) Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
FR2841900B1 (fr) Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
CY2014038I1 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
IL211367A0 (en) An antibody, a fragment thereof, a method of preparing the same and a use of the antibody
NO331093B1 (no) Somatostatinanaloger, fremgangsmåte for fremstilling, farmasøytisk sammensetning og anvendelse derav.
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
ITPD20020138A1 (it) Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
CY1106682T1 (el) Ενωση λακταμης
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
CY2009017I1 (el) Μεθοδος για την παρασκευη 10, 11-διυδρο-10-υδροξυ-5η-διβενζο/β,f/αζεπινο-5-καρβοξαμιδιου και 10,11-διυδρο-10-οξο-5η-διβενζο/β,f/αζεπινο-5-καρβοξαμιδιου
ITMO20030057A0 (it) Dispositivo per la confezione,la miscelazione e l'applicazione di cemento osseo.
DE602004024902D1 (de) Verbesserte formulierung zur bereitstellung eines magensaftresitenten beschichtungsmaterials
NO20070351L (no) Materialer og fremgangsmater for forbedring av skalldyrhelse, -immunitet og -vekst
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
DK1406642T3 (da) Fremgangsmåde til polyvalent bakteriofag-fremstilling til behandling af bakterielle infektioner
TR200202195T2 (tr) 5-Yer değiştirmiş 1-(4-florofenil)-1,3- dihidroizobenzofuran'ın adım adım alkillenmesi
NO20031108D0 (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
DK1537132T3 (da) Salt af mortin-6-glucuronid
PT1408035E (pt) Metodo de preparacao de derivativos de 1.5-diaril-3-trifluorometilo-delta2-pirazolinas que sejam racemicos e enanciomericamente puros
EA200300768A1 (ru) Фармацевтическая композиция, содержащая циталопрам
HRP20070517A2 (en) Escitalopram hydrobromide and a method for the preparation thereof
DK1270562T3 (da) Cykliske alfa-amino-gamma-hydroxyamider, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger heraf